Literature DB >> 10674191

Pharmacotherapy of attention deficit hyperactivity disorder.

T Spencer1, J Biederman, T Wilens.   

Abstract

Despite a large body of literature documenting the effectiveness of medication in the treatment of ADHD, there has been public and professional concern regarding the possible inappropriate diagnosis and prescription of ADHD medications. Recently the Council of Scientific Affairs of the American Medical Association addressed these concerns in a scholarly review. Several factors were identified that contributed to existing controversies: (1) Like most psychiatric disorders, diagnostic criteria for ADHD are based on history and behavioral assessment. There are no pathognomonic laboratory or radiologic tests to confirm the diagnosis. (2) Attention deficit hyperactivity disorder is a chronic disorder and requires extended treatment. (3) Treatment includes potentially abusable medications. After a review of the voluminous literature, this distinguished panel concluded that ADHD is one of the best researched disorders in medicine; in fact, the overall data on its validity are far more compelling than for many other medical conditions. They also concluded that there was little evidence of widespread overdiagnosis or misdiagnosis of ADHD or of widespread overprescription of stimulants by physicians. Consistent with the current emphasis on cognitive dysregulation in ADHD, treatment concerns have expanded from a primarily behavioral focus to include enhancement of executive functions in scholastic as well as other settings. Although stimulants have been the most studied compounds, there is a considerable body of literature indicating an important role for other psychopharmacologic agents. Noradrenergic and dopaminergic modulation appears to be necessary for effective anti-ADHD treatment. In addition, promising evidence of newer cholinergic agents may provide other useful alternatives. As with all psychiatric disorders, comorbid conditions are prominent and may lead to high morbidity and disability if not addressed. As with other areas of medicine, it is sometimes necessary to use multiple agents to treat comorbidity or to achieve an effective response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10674191

Source DB:  PubMed          Journal:  Child Adolesc Psychiatr Clin N Am        ISSN: 1056-4993


  16 in total

1.  Osmotic release oral system (OROS) Methylphenidate-induced double incontinence: a case report.

Authors:  Ching-Shu Tang; Wen-Jiun Chou; Andrew T A Cheng
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Transcranial direct current brain stimulation decreases impulsivity in ADHD.

Authors:  Cheyenne Allenby; Mary Falcone; Leah Bernardo; E Paul Wileyto; Anthony Rostain; J Russell Ramsay; Caryn Lerman; James Loughead
Journal:  Brain Stimul       Date:  2018-04-23       Impact factor: 8.955

3.  The effects of rearing environment and chronic methylphenidate administration on behavior and dopamine receptors in adolescent rats.

Authors:  Kathryn E Gill; Thomas J R Beveridge; Hilary R Smith; Linda J Porrino
Journal:  Brain Res       Date:  2013-06-24       Impact factor: 3.252

Review 4.  Treatment of attention-deficit hyperactivity disorder.

Authors:  L Murray; D R Patel
Journal:  Indian J Pediatr       Date:  2001-01       Impact factor: 1.967

Review 5.  Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children?

Authors:  Mark S Gold; Kenneth Blum; Marlene Oscar-Berman; Eric R Braverman
Journal:  Postgrad Med       Date:  2014-01       Impact factor: 3.840

6.  Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.

Authors:  James C Ermer; Kerry Dennis; Mary B Haffey; Walter J Doll; Erik P Sandefer; Mary Buckwalter; Richard C Page; Brian Diehl; Patrick T Martin
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 7.  Molecular genetics of attention deficit hyperactivity disorder.

Authors:  Stephen V Faraone; Eric Mick
Journal:  Psychiatr Clin North Am       Date:  2010-03

8.  Gene x environment interactions for ADHD: synergistic effect of 5HTTLPR genotype and youth appraisals of inter-parental conflict.

Authors:  Molly Nikolas; Karen Friderici; Irwin Waldman; Katherine Jernigan; Joel T Nigg
Journal:  Behav Brain Funct       Date:  2010-04-16       Impact factor: 3.759

9.  Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis.

Authors:  Stephen V Faraone; Jan Buitelaar
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-09-10       Impact factor: 4.785

10.  Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study.

Authors:  Stacey Ageranioti Bélanger; Michel Vanasse; Schohraya Spahis; Marie-Pierre Sylvestre; Sarah Lippé; François L'heureux; Parviz Ghadirian; Catherine-Marie Vanasse; Emile Levy
Journal:  Paediatr Child Health       Date:  2009-02       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.